Catequentinib
Digestive System Neoplasms
Zhejiang UniversitySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Digestive System Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib Sichuan Cancer Hospital and Research Institute | Phase 3 | BB |
Cyclophosphamide Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1/2 | B |
Fludarabine Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1/2 | B |
Linifanib Abbott | Phase 3 | B |
Donafenib Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | B |
View all 16 →
Same molecule, other indications
Catequentinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →